Announced details
Medical literature searches, anti-aging compound searches, research into compounds that can be used in cosmetics and functional foods, and research into the use of industrial waste and plants
ジーンネット used the system on a trial basis for 3 months from December 2025 to February 2026, followed by full-scale implementation. Candidate substances were identified.
FRONTEO provides KIBIT Amanogawa to ジーンネット under a business relationship. Capital and personnel relationships are not disclosed.
Headquartered in Higashi Ward, Fukuoka City. Representative Director: Asuyama Kosei (明日山康生). Provides research reagents and equipment sales and research support services in fields including biotechnology, nanotechnology and regenerative medicine. Capital and year of establishment, other than its location, are not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
PubMed (the biomedical and life sciences literature database of the U.S. National Library of Medicine and the National Center for Biotechnology Information)
| Item | Details |
|---|---|
| Names of Products / Services Covered | KIBIT Amanogawa (AI system for searching medical literature) |
| Counterparty | 株式会社ジーンネット |
| Counterparty overview | Headquartered in Higashi Ward, Fukuoka City. Representative Director: Asuyama Kosei (明日山康生). Provides research reagents and equipment sales and research support services in fields including biotechnology, nanotechnology and regenerative medicine. Capital and year of establishment, other than its location, are not disclosed. |
| Relationship with the Company | FRONTEO provides KIBIT Amanogawa to ジーンネット under a business relationship. Capital and personnel relationships are not disclosed. |
| Launch date | Full-scale implementation is underway. The specific start date is not disclosed. The trial use period was from December 2025 to February 2026. |
| Applicable area | Medical literature searches, anti-aging compound searches, research into compounds that can be used in cosmetics and functional foods, and research into the use of industrial waste and plants |
| Usage history | ジーンネット used the system on a trial basis for 3 months from December 2025 to February 2026, followed by full-scale implementation. Candidate substances were identified. |
| Source | PubMed (the biomedical and life sciences literature database of the U.S. National Library of Medicine and the National Center for Biotechnology Information) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The results achieved during the trial were favorably evaluated. The system will be used to streamline literature reviews and strengthen the research base in order to advance research into compounds of interest.